moderate to severe left ventricular dysfunction. This includes patients with longstanding disease, the presence of an S, gallop, cardiomegaly on chest X-ray, and New York Heart Association functional class III or IV disease. It is important to note that digoxin can be safely used in patients with concomitant coronary artery disease, as myocardial oxygen consumption may be unchanged or slightly reduced. " In 1990 randomized, double-blind, controlled trials were subjected to meta-analysis to assess the clinical usefulness of digoxin for patients with CHF in sinus rhythm. Seven trials meeting strict methodologic criteria were evaluated. The data suggest that on average, one of nine patients with CHF and sinus rhythm will benefit from digoxin." Unfortunately, the optimal dose of digoxin is not readily apparent. Despite this apparent limited utility for digoxin, it will continue to assume a role in the management of CHF. Perhaps its proper place will be for patients exhibiting significant systolic dysfunction and the more severe forms of CHF as the literature suggests. The onus is on the clinician to weigh the available evidence and make a decision that will result in the best therapeutic outcome for the patient. The ultimate success or failure of digoxin in the management of CHF may only be realized following a randomized controlled trial with the patient in question; n = 1. 10 CHARLES D. PONTE, Pharm.D., CDE
Professor of Clinical Pharmacy and Family Medicine School of Pharmacy West Virginia University Morgantown, West Virginia 26506
Comment: metered-dose inhalers TO THE EDITOR: In our article on the evaluation of pharmacists' practice in patient education when dispensing a metered-dose inhaler (DICP 1990;24:927-30), we neglected to include a point of clarification in Table I . As pointed out in our methods, controversial steps regarding inhalation technique were written to accept some different viewpoints as being correct (e.g., open vs. closed mouth technique with beta agonists). With this in mind, we intended to include in Table  I the instruction to exhale slowly and fully or to exhale to functional residual capacity (i.e., slowly exhale a normal breath to the resting level). We are concerned that the way Table I appears, the point may not be clear. Our Reference 17 (Newmanetal., Eur J RespirDis 1981;62: [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] ) is a classic review of inhalation techniques and controversies, and we refer interested readers to that article. Despite our findings in this project, we are aware of several pharmacists in Tennessee who routinely demonstrate MOl use in community pharmacies and observe patient use. Unfortunately, we believe that the percentage of pharmacists in Tennessee and across the U.S. is quite low. On the other hand, we are optimistic about recent graduates of many schools of pharmacy who are educated regarding MOl and spacer techniques. It is hoped these graduates will be diligent in educating patients.
Letters
This topic is increasingly important for the ten million people in this country with asthma because aerosols, including inhaled steroids and/or cromolyn, are the cornerstone of therapy. I Likewise, for the roughly 13 million chronic obstructive pulmonary disease patients in the U. S. , aerosols via MDIs are an important part of therapy. 
